Literature DB >> 28983040

Broadly neutralizing antibodies to prevent HIV-1.

Myron S Cohen1, Lawrence Corey2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28983040     DOI： 10.1126/science.aap8131

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  7 in total

1.  Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody.

Authors:  Srilatha Edupuganti; Nyaradzo Mgodi; Shelly T Karuna; Philip Andrew; Erika Rudnicki; Nidhi Kochar; Allan deCamp; Robert De La Grecca; Maija Anderson; Carissa Karg; India Tindale; Elizabeth Greene; Gail B Broder; Jonathan Lucas; John Hural; Jorge A Gallardo-Cartagena; Pedro Gonzales; Ian Frank; Magdalena Sobieszczyk; Margarita M Gomez Lorenzo; David Burns; Peter L Anderson; Maurine D Miner; Julie Ledgerwood; John R Mascola; Peter B Gilbert; Myron S Cohen; Lawrence Corey
Journal:  J Acquir Immune Defic Syndr       Date:  2021-05-01       Impact factor: 3.771

2.  A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings.

Authors:  Nyaradzo M Mgodi; Simbarashe Takuva; Srilatha Edupuganti; Shelly Karuna; Philip Andrew; Erica Lazarus; Precious Garnett; Emily Shava; Pamela G Mukwekwerere; Nidhi Kochar; Kyle Marshall; Erika Rudnicki; Michal Juraska; Maija Anderson; Carissa Karg; India Tindale; Elizabeth Greene; Nandisile Luthuli; Kagisho Baepanye; John Hural; Margarita M Gomez Lorenzo; David Burns; Maurine D Miner; Julie Ledgerwood; John R Mascola; Deborah Donnell; Myron S Cohen; Lawrence Corey
Journal:  J Acquir Immune Defic Syndr       Date:  2021-05-01       Impact factor: 3.771

3.  Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.

Authors:  Raphael J Landovitz; Sue Li; Beatriz Grinsztejn; Halima Dawood; Albert Y Liu; Manya Magnus; Mina C Hosseinipour; Ravindre Panchia; Leslie Cottle; Gordon Chau; Paul Richardson; Mark A Marzinke; Craig W Hendrix; Susan H Eshleman; Yinfeng Zhang; Elizabeth Tolley; Jeremy Sugarman; Ryan Kofron; Adeola Adeyeye; David Burns; Alex R Rinehart; David Margolis; William R Spreen; Myron S Cohen; Marybeth McCauley; Joseph J Eron
Journal:  PLoS Med       Date:  2018-11-08       Impact factor: 11.069

Review 4.  Sexually transmitted infections and HIV in the era of antiretroviral treatment and prevention: the biologic basis for epidemiologic synergy.

Authors:  Myron S Cohen; Olivia D Council; Jane S Chen
Journal:  J Int AIDS Soc       Date:  2019-08       Impact factor: 5.396

5.  Broadly neutralizing monoclonal antibodies for HIV prevention.

Authors:  Maurine D Miner; Lawrence Corey; David Montefiori
Journal:  J Int AIDS Soc       Date:  2021-11       Impact factor: 6.707

6.  Antibody bivalency improves antiviral efficacy by inhibiting virion release independently of Fc gamma receptors.

Authors:  Mehmet Sahin; Melissa M Remy; Benedict Fallet; Rami Sommerstein; Marianna Florova; Anna Langner; Katja Klausz; Tobias Straub; Mario Kreutzfeldt; Ingrid Wagner; Cinzia T Schmidt; Pauline Malinge; Giovanni Magistrelli; Shozo Izui; Hanspeter Pircher; J Sjef Verbeek; Doron Merkler; Matthias Peipp; Daniel D Pinschewer
Journal:  Cell Rep       Date:  2022-02-01       Impact factor: 9.423

Review 7.  Broadly Neutralizing Antibodies for HIV-1 Prevention.

Authors:  Stephen R Walsh; Michael S Seaman
Journal:  Front Immunol       Date:  2021-07-20       Impact factor: 7.561
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.